

Figure S1. Effect of LQB-118 on cell line attachment on the surface of culture flasks. U251-MG, A172 and T98G cells were photographed after treatment with LQB-118 6 μ M and 12 μ M. Contrast phase photomicrography representative of three independent experiments magnified 10 times. Scale bar, 100 μ m. GBM, glioblastoma.




Table SI. Combination index in A172 and U251-MG cells after LQB-118 combined treatment.

A172 (48 h)			U251 (48 h)		
CI grade symbols			CI grade symbols		
Cisplatin			Cisplatin		
LQB-118	3.0 μ M	30.0 μ M	LQB-118	3.0 μ M	30.0 μ M
3.0 μ M	1.01 \pm	0.95 \pm	3.0 μ M	0.55 ++	0.42 ++
6.0 μ M	0.97 \pm	1.77 - -	6.0 μ M	0.65 ++	0.53 ++
Temozolomide			Temozolomide		
LQB-118	50.0 μ M	100.0 μ M	LQB-118	50.0 μ M	100.0 μ M
3.0 μ M	1.43 -	1.25 -	3.0 μ M	0.62 ++	0.66 ++
6.0 μ M	1.33 -	1.92 - -	6.0 μ M	0.86 +	0.85

+ Synergism and antagonism were established based on CI determined by the Chou and Talalay method. The following grade symbols were adapted from Chou, 2016: Additive/nearly additive effect (\pm), CI: 0.9-1.1; moderate antagonism (-), CI: 1.1-1.5; antagonism (- -), CI: 1.5-3.3; Strong antagonism (- - -), CI >3.3; moderate synergism (+), CI: 0.7-0.9; synergism (++), CI: 0.3-0.7; Strong synergism (+++), CI <0.3. CI, combination index.